|
|
|
|
LEADER |
02143nam a2200325 u 4500 |
001 |
EB001897171 |
003 |
EBX01000000000000001060176 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
200523 r ||| eng |
245 |
0 |
0 |
|a Pharmacoeconomic review report: Latanoprostene bunod (Vyzulta)
|h Elektronische Ressource
|b (Bausch Health Canada Inc.)
|
246 |
3 |
1 |
|a Latanoprostene bunod (Vyzulta)
|
246 |
3 |
1 |
|a Pharmacoeconomic review report for Vyzulta
|
250 |
|
|
|a Version: final
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c August 2019, 2019
|
300 |
|
|
|a 1 PDF file (33 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Ocular Hypertension / drug therapy
|
653 |
|
|
|a Glaucoma, Open-Angle / drug therapy
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Prostaglandins F, Synthetic / therapeutic use
|
653 |
|
|
|a Treatment Outcome
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review
|
856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK549683
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a Latanoprostene bunod (LBN) 0.024% ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). It is available as a sterile topical ophthalmic solution containing 0.24 mg/mL LBN supplied in an eye-drop dispenser with a 5 mL fill volume. The recommended dosage is one drop in the affected eye(s) once daily. At the manufacturer-submitted price of $26.25 per dispenser, LBN costs approximately $0.30 per day, assuming treatment of both eyes. The manufacturer submitted a cost-utility analysis comparing LBN with currently available prostaglandin analogues (PGAs) for the treatment of patients with OHT and OAG (bimatoprost 0.01%, bimatoprost 0.03%, generic latanoprost 0.005%, and travoprost 0.004%). All patients were assumed to have both eyes treated
|